Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release

Neurourology and Urodynamics

Volumn 29, Issue 4, 2010, Pages 551-554

  Chancellor, Michael B ^a   Oefelein, Michael G ^b   Vasavada, Sandip ^c  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b ALLERGAN INC   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Incontinence; Leakage; Obesity; Overactive bladder syndrome; Trospium; Urge incontinence; Urgency

Indexed keywords

PLACEBO; TROSPIUM CHLORIDE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; OBESITY; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY URGENCY; URINE INCONTINENCE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NORTROPANES; OBESITY; OVERWEIGHT; PARASYMPATHOLYTICS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 77953573487     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20787     Document Type: Article

References (19)

1. Hunskaar S. A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women. Neurourol Urodyn 2008;27:749-757
2. Moller L, Lose G, Jorgensen T, et al. Risk factors for lower urinary tract symptoms in women 40 to 60 years of age. Obstet Gynecol 2000;96:446-451
3. Auwad W, Steggles P, Bombieri L, et al. Moderate weight loss in obese women with urinary incontinence: A prospective longitudinal study. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:1251-1259
4. Brown JS, Seeley DG, Fong J, et al. Urinary incontinence in older women: Who is at risk? Study of Osteoporotic Fractures Research Group. Obstet Gynecol 1996; 87:715-721
5. Cummings JM, Rodning CB. Urinary stress incontinence among obese women: Review of pathophysiology therapy. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:41-44
6. Hannestad YS, Rortveit G, Daltveit AK, et al. Are smoking and other lifestyle factors associated with female urinary incontinence. The Norwegian EPINCONT study. BJOG 2003;110:247-254
7. Dallosso HM, McGrother CW, Matthews RJ, et al. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: A longitudinal study in women. BJU Int 2003;92:69-77.
8. Dallosso HM, Matthews RJ, McGrother CW, et al. The association of diet and other lifestyle factors with the onset of overactive bladder: A longitudinal study in men. Public Health Nutr 2004;7:885-891
9. Stewart WF, Van Rooyen JB, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336
10. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: The Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001;97:116-120
11. Subak LL, Wing R, West DS, et al.Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009;360:481-490
12. Richter HE, Creasman JM, Myers DL, et al. Urodynamic characterization of obese women with urinary incontinence undergoing a weight loss program: The Program to Reduce Incontinence by Diet and Exercise (PRIDE) trial. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:1653-1658
13. Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: Results from a multicenter phase III trial. J Urol 2007;178:978-83; discussion 983-984
14. Dmochowski RR, Sand P, Zinner N, et al. Trospium 60mg once daily (QD) for overactive bladder syndrome: Results from a placebo-controlled interventional study. Urology 2008;71:449-454
15. Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005; 174:604-607
16. Tyagi P, Tyagi V, Witteemer E, et al. Expression of ghrelin receptor in bladder points to a new link between obesity and the overactive bladder. J Urol 2009;181:570.
17. Scheen AJ. Results of obesity treatment. Ann Endocrinol (Paris) 2002;63:70.
18. Doroshyenko O, Jetter A, Orenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005;44:701-720
19. Frohlich G, Burmeister S, Wiedermann A, et al. Intravesical instillation of trospium chloride, oxybutynin and verapamil to relax the detrussor muscle of the urinary bladder: A placebo controlled, randomized clinical trial. Drug Res 1998;48:486-491